Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Unknown × Tablets × Gastrointestinal × Clear all

Phase

Status

Completed 3 Recruiting 2 Not yet recruiting 2 Unknown 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 2 Thoracic 1 Genitourinary 1 Gastrointestinal 1 Dermatologic 1 CNS 1

Conditions

Resectable Pancreatic Ductal Adenocarcinoma 1

Interventions

Oxaliplatin 253 Capecitabine 192 Fluorouracil 185 Irinotecan 133 Leucovorin 116 apatinib 104 Gemcitabine 104 S 1 (combination) 99 Radiotherapy 89 Drug Therapy 88 Bevacizumab 88 Paclitaxel 87 Cisplatin 86 camrelizumab 84 sintilimab 68 Cetuximab 68 Neoadjuvant Therapy 55 lenvatinib 54 tislelizumab 51 Sorafenib 48 Surgical Procedures, Operative 47 Folfox protocol 46 Docetaxel 45 toripalimab 44 130-nm albumin-bound paclitaxel 39 Laparoscopy 36 HMPL-013 36 XELOX 33 regorafenib 31 Chemotherapy, Adjuvant 31

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02978547 2018-01-18

Metformin 001

British Columbia Cancer Agency

Phase 2 Unknown

Gastrointestinal

Resectable Pancreatic Ductal Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡